Myelodysplastic Syndromes

Total Page:16

File Type:pdf, Size:1020Kb

Myelodysplastic Syndromes ® HEMATOLOGY BOARD REVIEW MANUAL STATEMENT OF EDITORIAL PURPOSE Myelodysplastic Syndromes The Hospital Physician Hematology Board Review Manual is a study guide for fellows and practicing physicians preparing for board Contributors: examinations in hematology. Each manual Jasleen Randhawa, MD reviews a topic essential to the current prac­ tice of hematology. Mazie Froedtert Willms and Sue Froedtert Cancer Fellow, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI PUBLISHING STAFF PRESIDENT, GROUP PUBLISHER Ehab Atallah, MD Bruce M. White Associate Professor of Medicine, Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI SENIOR EDITOR Robert Litchkofski EXECUTIVE VICE PRESIDENT Barbara T. White EXECUTIVE DIRECtor OF OPERAtions Table of Contents Jean M. Gaul Introduction ................................. 1 Epidemiology, Etiology, and Pathogenesis ........ 1 Clinical Features ........................... 1 Merck is pleased to provide this Classification and Risk Stratification ............ 2 material as a professional service to the medical community. Molecular Basis of MDS ..................... 4 Intermediate-1-Risk MDS ................... 5 5Q-Deletion Syndrome ..................... 8 High-Risk MDS with Del(5q) .................. 9 High-Risk MDS ........................... 10 NOTE FROM THE PUBLISHER: Summary ............................... 11 This publication has been developed with­ out involvement of or review by the Amer­ Board Review Questions .................... 11 ican Board of Internal Medicine. References ................................. 11 Copyright 2014, Turner White Communications, Inc., Strafford Avenue, Suite 220, Wayne, PA 19087-3391, www.turner-white.com. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, mechanical, electronic, photocopying, recording, or otherwise, without the prior written permission of Turner White Communications. The preparation and distribution of this publication are supported by sponsorship subject to written agreements that stipulate and ensure the editorial independence of Turner White Communications. Turner White Communications retains full control over the design and production of all published materials, including selection of topics and preparation of editorial content. The authors are solely respon- sible for substantive content. Statements expressed reflect the views of the authors and not necessarily the opinions or policies of Turner White Communications. Turner White Communications accepts no responsibility for statements made by authors and will not be liable for any errors of omission or inaccuracies. Information contained within this publication should not be used as a substitute for clinical judgment. HEMATOLOGY BOARD REVIEW MANUAL Myelodysplastic Syndromes Jasleen Randhawa, MD, and Ehab Atallah, MD INTRODUCTION CLINICAL FEATURES Myelodysplastic syndromes (MDS) are a spectrum Clinically, MDS is usually suspected when a patient of clonal myeloid disorders characterized by ineffec- undergoes evaluation for cytopenias. A bone marrow tive hematopoiesis, cytopenias, qualitative disorders biopsy is essential to establish the diagnosis of MDS, of blood cells, clonal chromosomal abnormalities, which is confirmed by the presence of dysplasia. Biop- and the potential for clonal evolution to acute my- sy also helps to determine the marrow cellularity and eloid leukemia (AML).1 In this review, we discuss architecture, including morphology, and allows for the various pathogenic conditions included in the detailed evaluation of blasts. Cytogenetic evaluation spectrum of MDS and the associated risk stratification of 20 metaphases is required to determine the cytoge- for these conditions. We further discuss the treatment netic patterns. At this time, there is no definitive data recommendations based on the risk status and the showing that flow cytometry or fluorescence in situ expected prognosis. hybridization (FISH) analysis is better at establishing the phenotype than conventional cytogenetics.9 Fatigue and other symptoms secondary to anemia EPIDEMIOLOGY, ETIOLOGY, AND PATHOGENESIS may be seen. The patient may have repeated infections due to severe neutropenia or neutrophil dysfunction In the western population, the onset of MDS usu- and bleeding due to thrombocytopenia or platelet ally occurs after age 50 years, except in cases where dysfunction. Fever may occur as a result of the disease the individual has undergone radiation therapy or itself, irrespective of infection. Hepatomegaly and sple- chemotherapy for a prior malignancy.2,3 The annual nomegaly can occur in 5% to 10% of cases.10 incidence of MDS increases in a logarithmic fash- Less common manifestations of MDS may include ion after the age of 40 years. According to National diabetes. Hypothalamic-posterior pituitary insuffi- Cancer Institute data, the annual incidence of MDS ciency in clonal myeloid states has been associated increases from 2 per 1 million persons at age 40 years with monosomy 7 in the hematopoietic cells, and to more than 40 per 100,000 persons in the septua- these patients experience polyuria, polydipsia, and genarian population. Males are affected 1.5 times as decreased libido.11 Immune or inflammatory syn- often as females.2 dromes have been reported in up to 10% of cases. The etiologic factors that have been associated Some patients may exhibit a syndrome suggestive with increased incidence of MDS are similar to those of systemic lupus erythematosus with fever, pleurisy, that have been associated with increased AML inci- arthritis, and positive plasma antinuclear antibodies dence. These factors include prolonged exposure to preceding progression to AML.12,13 Behçet’s disease, high levels of benzene, alkylating agents, topoisomer- systemic vasculitis, inflammatory bowel disease, sero- ase inhibitors, and radiation.4,5 negative arthritis, and glomerulonephritis have also The major pathogenic mechanism in MDS is been reported with MDS.14–17 ineffective hematopoiesis, causing defective matu- Several laboratory abnormalities can be seen with ration and death of marrow precursors.6 More re- MDS. Iron and ferritin levels may be elevated due cently, significant strides have been made in un- to anemia and transfusions. Lactate dehydrogenase derstanding MDS at a molecular and cytogenetic and uric acid concentrations may be elevated due to level.7,8 Hopefully, this information will help im- a high death ratio of the marrow precursors. Other prove the prognostication of MDS and help indi- abnormalities include monoclonal gammopathy, vidualize therapy to each patient for the best possible hyper-/hypogammaglobulinemia, and increased β2 outcomes. microglobulin levels.18,19 www.hpboardreview.com Hematology Volume 9, Part 3 1 Myelodysplastic Syndromes Table 1. World Health Organization Classification of Myelodysplastic Syndromes Disease Peripheral Blood Findings Bone Marrow Findings Refractory cytopenia with unilineage dys- Single lineage cytopenia, no or rare blasts Unilineage dysplasia (≥10% of the cells in 1 myeloid plasia (RCUD): refractory anemia (RA), (<1%), bicytopenia may be occasionally lineage) <5% blasts, <15% ring sideroblasts within refractory neutropenia (RN), refractory observed erythroid precursors thrombocytopenia (RT) Refractory anemia with ring sideroblasts Anemia, no blasts Erythroid dysplasia only, <5% blasts, ≥15% ringed (RARS) sideroblasts within erythroid precursors Refractory cytopenia with multilineage Cytopenia(s), no or rare blasts (1%), no Dysplasia in ≥10% of cells in 2 or more myeloid cell dysplasia (RCMD) Auer roads, <1x109/L monocytes lineages, <5% blasts, no Auer roads Refractory anemia with excess blasts-1 Cytopenia(s), <5% blasts, no Auer roads, Unilineage or multilineage dysplasia, 5% to 9% (RAEB-1) <1x109/L monocytes (cases with Auer blasts, no Auer roads (cases with Auer rods and rods and <5% blasts in the peripheral <5% blasts in the peripheral blood and <10% blood and <10% blasts in the marrow blasts in the marrow should be classified as should be classified as RAEB-2) RAEB-2) Refractory anemia with excess blasts-2 Cytopenia(s), 5%–19% blasts, occasional Unilineage or multilineage dysplasia, 10%–19% (RAEB-2) Auer roads, <1x109/L monocytes blasts, occasional Auer roads Myelodysplastic syndrome, unclassified Cytopenias, no or rare blasts (≤1%) Unequivocal dysplasia in <10% of cells in 1 or more (MDS-U) myeloid cell lines when accompanied by a cyto- genetic abnormality considered as presumptive evidence for a diagnosis of MDS, <5% blasts *Cases of RCUD with pancytopenia *Cases of RCUD and RCMD with 1% myeloblasts in peripheral blood Myelodysplastic syndrome associated with Anemia, normal to increased platelet Anemia, normal to increased platelet count, no or isolated del(5q) count, no or rare blasts (<1%) rare blasts (<1%) Reprinted with permission from Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937–51. Several prognostic systems have been devised for the CLASSIFICATION AND RISK STRATIFICATION risk stratification of patients with MDS. These include the International Prognostic Scoring System (IPSS, The World Health Organization (WHO) has de- Table 2),23 the revised IPSS (R-IPSS, Table 3),24 WHO vised a classification to overcome
Recommended publications
  • Prognostic Biomarkers in Myelodysplastic Syndromes
    Myelodysplastic syndromes Prognostic biomarkers in myelodysplastic syndromes M. Cazzola ABSTRACT Prognostic biomarkers in myelodysplastic syndromes (MDS) include cytogenetic abnormalities and Department of Hematology somatic gene mutations. Recurrent chromosomal abnormalities are found in approximately 50% of Oncology, Fondazione Istituto cases, and are mainly secondary genetic events. By contrast, somatic oncogenic mutations, responsible di Ricovero e Cura a Carattere for disease pathogenesis and progression, are found in up to 90% of MDS patients. Oncogenic muta - Scientifico (IRCCS) Policlinico tions can be classified as: i) founding or initiating driver mutations, which cause a selective advantage San Matteo, and Department in a hematopoietic cell with capacity for self-renewal and lead to formation of a clone of mutated of Molecular Medicine, myelodysplastic cells; ii) subclonal or cooperating driver mutations, which occur in cells of an already University of Pavia, Pavia, Italy established clone and generate subclones carrying both the founding and the newly acquired muta - tion. Driver mutant genes include those of RNA splicing, DNA methylation, histone modification, tran - Correspondence: Mario Cazzola scription regulation, DNA repair, signal transduction, and cohesin complex. Only 6 genes ( TET2, SF3B1, E-mail: [email protected] ASXL1, SRSF2, DNMT3A , and RUNX1 ) are consistently mutated in 10% or more of MDS patients, while Acknowledgments: a long tail of additional genes are mutated less frequently. Reliable genotype/phenotype relationships The studies on the genetic basis of have already been established, primarily the close association between SF3B1 mutation and ring sider - myeloid neoplasms conducted at the oblasts. Clonal and subclonal mutations appear to affect prognosis equally, and outcome correlates Department of Hematology with the number of driver mutations.
    [Show full text]
  • (NCCN Guidelines®) Myelodysplastic Syndromes Version 2.2018 — February 15, 2018
    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Myelodysplastic Syndromes Version 2.2018 — February 15, 2018 NCCN.org NCCN Guidelines for Patients® available at www.nccn.org/patients Continue Version 2.2018, 02/15/18 © National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®. NCCN Guidelines Version 2.2018 NCCN Guidelines Index Table of Contents Myelodysplastic Syndromes Discussion *Peter L. Greenberg, MD/Chair ‡ Þ Karin Gaensler, MD ‡ Lori J. Maness, MD ‡ Stanford Cancer Institute UCSF Helen Diller Family Fred & Pamela Buffett Cancer Center Comprehensive Cancer Center *Richard M. Stone, MD/Vice Chair ‡ † Margaret R. O’Donnell, MD ‡ Dana-Farber/Brigham and Women’s Guillermo Garcia-Manero, MD ‡ City of Hope Comprehensive Cancer Center Cancer Center The University of Texas MD Anderson Cancer Center Daniel A. Pollyea, MD Þ † ‡ Aref Al-Kali, MD ‡ University of Colorado Cancer Center Mayo Clinic Cancer Center Elizabeth A. Griffiths, MD Þ † ‡ Roswell Park Cancer Institute Vishnu V. Reddy, MD ≠ † John M. Bennett, MD Þ † ≠ University of Alabama at Birmingham Consultant David Head, MD ≠ Comprehensive Cancer Center Vanderbilt-Ingram Cancer Center Hetty Carraway, MD † ‡ Paul J. Shami, MD ‡ Case Comprehensive Cancer Center/University Ruth Horsfall, PhD, MSc ¥ Huntsman Cancer Institute Hospitals Seidman Cancer Center and Patient Advocate at the University of Utah Cleveland Clinic Taussig Cancer Institute Robert A. Johnson, MD † Alison R. Walker, MD ‡ Peter Curtin, MD† ‡ St. Jude Children’s Research Hospital/The University The Ohio State University Comprehensive UC San Diego Moores Cancer Center of Tennessee Health Science Center Cancer Center - James Cancer Hospital and Solove Research Institute Carlos M.
    [Show full text]
  • Minimal Morphological Criteria for Defining Bone Marrow
    Leukemia (2015) 29, 66–75 & 2015 Macmillan Publishers Limited All rights reserved 0887-6924/15 www.nature.com/leu ORIGINAL ARTICLE Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes MG Della Porta1,2,13, E Travaglino1,13, E Boveri3,13, M Ponzoni4, L Malcovati1,5, E Papaemmanuil6, GM Rigolin7, C Pascutto1, G Croci3,5, U Gianelli8, R Milani4, I Ambaglio1, C Elena1, M Ubezio1,5, MC Da Via’1,5, E Bono1,5, D Pietra1, F Quaglia2, R Bastia2, V Ferretti1, A Cuneo7, E Morra9, PJ Campbell6,10,11, A Orazi12,RInvernizzi2,14 and M Cazzola1,5,14 on behalf of Rete Ematologica Lombarda (REL) clinical network The World Health Organization classification of myelodysplastic syndromes (MDS) is based on morphological evaluation of marrow dysplasia. We performed a systematic review of cytological and histological data from 1150 patients with peripheral blood cytopenia. We analyzed the frequency and discriminant power of single morphological abnormalities. A score to define minimal morphological criteria associated to the presence of marrow dysplasia was developed. This score showed high sensitivity/specificity (490%), acceptable reproducibility and was independently validated. The severity of granulocytic and megakaryocytic dysplasia significantly affected survival. A close association was found between ring sideroblasts and SF3B1 mutations, and between severe granulocytic dysplasia and mutation of ASXL1, RUNX1, TP53 and SRSF2 genes. In myeloid neoplasms with fibrosis, multilineage dysplasia, hypolobulated/multinucleated megakaryocytes and increased CD34 þ progenitors in the absence of JAK2, MPL and CALR gene mutations were significantly associated with a myelodysplastic phenotype. In myeloid disorders with marrow hypoplasia, granulocytic and/or megakaryocytic dysplasia, increased CD34 þ progenitors and chromosomal abnormalities are consistent with a diagnosis of MDS.
    [Show full text]
  • When Should We Think of Myelodysplasia Or Bone Marrow Failure in a Thrombocytopenic Patient? a Practical Approach to Diagnosis
    Journal of Clinical Medicine Review When Should We Think of Myelodysplasia or Bone Marrow Failure in a Thrombocytopenic Patient? A Practical Approach to Diagnosis Nicolas Bonadies 1,2,† , Alicia Rovó 1,† , Naomi Porret 1 and Ulrike Bacher 1,* 1 Department of Hematology and Central Hematology Laboratory, Inselspital Bern, University of Bern, 3010 Bern, Switzerland; [email protected] (N.B.); [email protected] (A.R.); [email protected] (N.P.) 2 Department for BioMedical Research, University of Bern, 3008 Bern, Switzerland * Correspondence: [email protected]; Tel.: +41-31-632-1390; Fax: +41-31-632-3406 † Equal contribution. Abstract: Thrombocytopenia can arise from various conditions, including myelodysplastic syn- dromes (MDS) and bone marrow failure (BMF) syndromes. Meticulous assessment of the peripheral blood smear, identification of accompanying clinical conditions, and characterization of the clinical course are important for initial assessment of unexplained thrombocytopenia. Increased awareness is required to identify patients with suspected MDS or BMF, who are in need of further investigations by a step-wise approach. Bone marrow cytomorphology, histopathology, and cytogenetics are comple- mented by myeloid next-generation sequencing (NGS) panels. Such panels are helpful to distinguish reactive cytopenia from clonal conditions. MDS are caused by mutations in the hematopoietic Citation: Bonadies, N.; Rovó, A.; stem/progenitor cells, characterized by cytopenia and dysplasia, and an inherent risk of leukemic Porret, N.; Bacher, U. When Should progression. Aplastic anemia (AA), the most frequent acquired BMF, is immunologically driven and We Think of Myelodysplasia or Bone characterized by an empty bone marrow. Diagnosis remains challenging due to overlaps with other Marrow Failure in a hematological disorders.
    [Show full text]
  • Myeloproliferative Neoplasms - Clinical Merase Chain Reaction (PCR).The Patient Was Treated with Imatinib and Achieved Hematologic and Cytogenetic Remission
    Stockholm, Sweden, June 13 – 16, 2013 cific amplification of the genomic breakpoints and reverse transcription poly - Myeloproliferative neoplasms - Clinical merase chain reaction (PCR).The patient was treated with imatinib and achieved hematologic and cytogenetic remission. Minimal residual disease screening over 3 years with nested PCR failed to detect CEP85L-PDGFRB B1556 mRNA or genomic DNA, confirming a long term molecular remission on ima - RECURRENT CEP85L-PDGFRB FUSION IN A PATIENT WITH A TRANSLO - tinib. In our view, the detection of the exact gene fusion is clinically relevant for CATION T(5;6) AND AN IMATINIB-RESPONSIVE MYELOPROLIFERATIVE effective long term management of these neoplasms as it enables specific fol - NEOPLASM WITH EOSINOPHILIA low up by sensitive molecular analysis. N Winkelmann 1,2* , C Hidalgo-Curtis 1,3, K Waghorn 1,3, J Score 1,3, H Dickin - son 4, A Jack 5, S Ali 6, N Cross 1,3 1Leukaemia Research Group , Wessex Regional Genetics Laboratory, Salis - B1557 bury, United Kingdom, 2Klinik für Innere Medizin II , Universitätsklinikum Jena, CLINICAL SIGNIFICANCE OF IMMATURE PLATELET FRACTION IN BCR- Jena, Germany, 3Faculty of Medicine, University of Southampton, Southamp - ABL1-NEGATIVE CHRONIC MYELOPROLIFERATIVE NEOPLASMS ton, 4Cytogenetics Unit, St. James´s University Hospital, 5Haematological N Vazzana 1* , R Spadano 1, S Di Zacomo 2, G Rolandi 3, A Dragani 1 Malignancy Diagnostic Service, St James’s University Hospital, Leeds, 6Hull 1Department of Hematology, Centre for Hemophilia and Rare Blood Disorders, Royal Infirmary, Hull Royal Infirmary, Hull, United Kingdom 2Department of Transfusion Medicine, Molecular Biology Unit, 3Department of Transfusion Medicine, Coagulation Unit, Pescara, Italy Background: Fusion genes involving the catalytic domain of tyrosine kinases (TKs) play an important role in the pathogenesis of hematological malignancies Background: Platelet activation plays a pivotal role in the pathogenesis of and solid tumors.
    [Show full text]
  • Myelodysplastic Syndromes — Coping with Ineffective
    PERSPECTIVE Myelodysplastic Syndromes — Coping with Ineffective Hematopoiesis Myelodysplastic Syndromes — Coping with Ineffective Hematopoiesis Mario Cazzola, M.D., and Luca Malcovati, M.D. Related article, page 549 One of the most challenging problems in hema- cytes. Families with an inherited genetic predispo- tology is the heterogeneous group of disorders sition and multistep progression to a myelodysplas- that were formally defined as myelodysplastic syn- tic syndrome and acute myeloid leukemia have been dromes by the French–American–British Coopera- reported1 but are extremely rare. Whether idiopath- tive Group in 1982. This set of disorders includes ic myelodysplastic syndromes are truly clonal pro- idiopathic conditions as well as the secondary or liferations of multipotent stem cells, however, is un- therapy-related forms that develop after exposure clear. The biologic hallmark of these stem cells in to alkylating agents, radiation, or both. Idiopathic myelodysplastic syndromes is, rather, a defective myelodysplastic syndromes occur mainly in older capacity for self-renewal and differentiation. The persons: the incidence of these syndromes is about consequences of this abnormality are probably am- 5 per 100,000 persons per year in the general pop- plified in the elderly because the aging process it- ulation, but it increases to 20 to 50 per 100,000 per- self may not only deplete stem cells, but also alter sons per year after 60 years of age. Approximate- the marrow microenvironment, particularly in per- ly 15,000 new cases are expected in the United sons with occupational or environmental exposure States each year, indicating that myelodysplastic to chemical and physical hazards. The resulting per- syndromes are at least as common as chronic lym- turbed interactions between hematopoietic progen- phocytic leukemia, the most prevalent form of leu- itors and marrow stromal cells are probably respon- kemia in Western countries.
    [Show full text]
  • Standardization of Flow Cytometry in Myelodysplastic Syndromes
    Leukemia (2012) 26, 1730 --1741 & 2012 Macmillan Publishers Limited All rights reserved 0887-6924/12 www.nature.com/leu SPECIAL REPORT Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group TM Westers1, R Ireland2,24, W Kern3,24, C Alhan1, JS Balleisen4, P Bettelheim5, K Burbury6, M Cullen7, JA Cutler8, MG Della Porta9, AM Dra¨ger1, J Feuillard10, P Font11, U Germing4, D Haase12, U Johansson13, S Kordasti2, MR Loken8, L Malcovati9, JG te Marvelde14, S Matarraz15, T Milne2, B Moshaver16, GJ Mufti2, K Ogata17, A Orfao15, A Porwit18, K Psarra19, SJ Richards7, D Subira´ 20, V Tindell2, T Vallespi21, P Valent22, VHJ van der Velden14, TM de Witte16, DA Wells8, F Zettl12,MCBe´ne´ 23 and AA van de Loosdrecht1,24 Flow cytometry (FC) is increasingly recognized as an important tool in the diagnosis and prognosis of myelodysplastic syndromes (MDS). However, validation of current assays and agreement upon the techniques are prerequisites for its widespread acceptance and application in clinical practice. Therefore, a working group was initiated (Amsterdam, 2008) to discuss and propose standards for FC in MDS. In 2009 and 2010, representatives from 23, mainly European, institutes participated in the second and third European LeukemiaNet (ELN) MDS workshops. In the present report, minimal requirements to analyze dysplasia are refined. The proposed core markers should enable a categorization of FC results in cytopenic patients as ‘normal’, ‘suggestive of’, or ‘diagnostic of’ MDS. An FC report should include a description of validated FC abnormalities such as aberrant marker expression on myeloid progenitors and, furthermore, dysgranulopoiesis and/or dysmonocytopoiesis, if at least two abnormalities are evidenced.
    [Show full text]
  • Mediterranean Journal Od Hematology and Infectious Diseases
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Crossref Mediterranean Journal of Hematology and Infectious Diseases Review article Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes. Matteo G. Della Porta1 and Cristina Picone2 1 Cancer Center, Humanitas Research Hospital & Humanitas University, Rozzano – Milan, Italy. 2 Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia Italy. Competing interests: The authors have declared that no competing interests exist. Abstract. The pathological hallmark of myelodysplastic syndromes (MDS) is marrow dysplasia, which represents the basis of the WHO classification of these disorders. This classification provides clinicians with a useful tool for defining the different subtypes of MDS and individual prognosis. The WHO proposal has raised some concern regarding minimal diagnostic criteria particularly in patients with normal karyotype without robust morphological markers of dysplasia (such as ring sideroblasts or excess of blasts). Therefore, there is clearly need to refine the accuracy to detect marrow dysplasia. Flow cytometry (FCM) immunophenotyping has been proposed as a tool to improve the evaluation of marrow dysplasia. The rationale for the application of FCM in the diagnostic work up of MDS is that immunophenotyping is an accurate method for quantitative and qualitative evaluation of hematopoietic cells and that MDS have been found to have abnormal expression of several cellular antigens. To become applicable in clinical practice, FCM analysis should be based on parameters with sufficient specificity and sensitivity, data should be reproducible between different operators, and the results should be easily understood by clinicians. In this review, we discuss the most relevant progresses in detection of marrow dysplasia by FCM in MDS Keywords: Myelodysplastic Syndrome; Flow Cytometry; Diagnostic Tools.
    [Show full text]
  • Standardization of Flow Cytometry in Myelodysplastic Syndromes
    Leukemia (2012) 26, 1730 --1741 & 2012 Macmillan Publishers Limited All rights reserved 0887-6924/12 www.nature.com/leu SPECIAL REPORT Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group TM Westers1, R Ireland2,24, W Kern3,24, C Alhan1, JS Balleisen4, P Bettelheim5, K Burbury6, M Cullen7, JA Cutler8, MG Della Porta9, AM Dra¨ger1, J Feuillard10, P Font11, U Germing4, D Haase12, U Johansson13, S Kordasti2, MR Loken8, L Malcovati9, JG te Marvelde14, S Matarraz15, T Milne2, B Moshaver16, GJ Mufti2, K Ogata17, A Orfao15, A Porwit18, K Psarra19, SJ Richards7, D Subira´ 20, V Tindell2, T Vallespi21, P Valent22, VHJ van der Velden14, TM de Witte16, DA Wells8, F Zettl12,MCBe´ne´ 23 and AA van de Loosdrecht1,24 Flow cytometry (FC) is increasingly recognized as an important tool in the diagnosis and prognosis of myelodysplastic syndromes (MDS). However, validation of current assays and agreement upon the techniques are prerequisites for its widespread acceptance and application in clinical practice. Therefore, a working group was initiated (Amsterdam, 2008) to discuss and propose standards for FC in MDS. In 2009 and 2010, representatives from 23, mainly European, institutes participated in the second and third European LeukemiaNet (ELN) MDS workshops. In the present report, minimal requirements to analyze dysplasia are refined. The proposed core markers should enable a categorization of FC results in cytopenic patients as ‘normal’, ‘suggestive of’, or ‘diagnostic of’ MDS. An FC report should include a description of validated FC abnormalities such as aberrant marker expression on myeloid progenitors and, furthermore, dysgranulopoiesis and/or dysmonocytopoiesis, if at least two abnormalities are evidenced.
    [Show full text]
  • Impaired Hematopoiesis and Leukemia Development in Mice with a Conditional Knock-In Allele of a Mutant Splicing Factor Gene U2af1
    Impaired hematopoiesis and leukemia development in mice with a conditional knock-in allele of a mutant splicing factor gene U2af1 Dennis Liang Feia,b,c,1,2, Tao Zhend,1, Benjamin Durhame, John Ferraronea,b, Tuo Zhangf,g, Lisa Garretth, Akihide Yoshimie, Omar Abdel-Wahabe,i, Robert K. Bradleyj,k, Paul Liud,2, and Harold Varmusa,b,c,l,2 aDepartment of Medicine, Weill Cornell Medicine, New York, NY 10065; bMeyer Cancer Center, Weill Cornell Medicine, New York, NY 10065; cCancer Biology Section, Cancer Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892; dOncogenesis and Development Section, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892; eHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065; fGenomics Resources Core Facility, Weill Cornell Medicine, New York, NY 10065; gDepartment of Microbiology and Immunology, Weill Cornell Medicine, New York, NY 10065; hEmbryonic Stem Cell and Transgenic Mouse Core, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892; iLeukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065; jComputational Biology Program, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109; kBasic Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109; and lNew York Genome Center, New York, NY 10013 Contributed by Harold Varmus, September 15, 2018 (sent for review July 26, 2018; reviewed by Benjamin L. Ebert and Stephanie Halene) Mutations affecting the spliceosomal protein U2AF1 are commonly addition, U2AF1(S34F) is present at high allelic frequencies (nearly found in myelodysplastic syndromes (MDS) and secondary acute 50%) in MDS (6), seems to predispose MDS patients to secondary myeloid leukemia (sAML).
    [Show full text]
  • Immunophenotypic Analysis of Erythroid Dysplasia in Myelodysplastic Syndromes
    Myelodysplastic Syndrome SUPPLEMENTARY APPENDIX Immunophenotypic analysis of erythroid dysplasia in myelodysplastic syndromes. A report from the IMDSFlow working group Theresia M. Westers, 1 Eline M.P. Cremers, 1 Uta Oelschlaegel, 2 Ulrika Johansson, 3 Peter Bettelheim, 4 Sergio Matarraz, 5 Alberto Orfao, 5 Bijan Moshaver, 6 Lisa Eidenschink Brodersen, 7 Michael R. Loken, 7 Denise A. Wells, 7 Dolores Subirá, 8 Matthew Cullen, 9 Jeroen G. te Marvelde, 10 Vincent H.J. van der Velden, 10 Frank W.M.B. Preijers, 11 Sung-Chao Chu, 12 Jean Feuillard, 13 Estelle Guérin, 13 Katherina Psarra, 14 Anna Porwit, 15,16 Leonie Saft, 16 Robin Ireland, 17 Timothy Milne, 17 Marie C. Béné, 18 Birgit I. Witte, 19 Matteo G. Della Porta, 20 Wolfgang Kern 21 and Arjan A. van de Loosdrecht, 1 on behalf of the IMDSFlow Working Group 1Department of Hematology, VU University Medical Center, Cancer Center Amsterdam, The Netherlands; 2Department of Internal Medi - cine, Universitätsklinikum “Carl-Gustav-Carus”, Dresden, Germany; 3Department of Haematology, University Hospitals NHS Foundation Trust, Bristol, UK; 4First Medical Department, Elisabethinen Hospital, Linz, Austria; 5Servicio Central de Citometría (NUCLEUS) and De - partment of Medicine, Centro de Investigación del Cáncer, Instituto de Biologia Celular y Molecular del Cáncer, (CSIC/USAL and IBSAL), Universidad de Salamanca, Spain; 6Isala Clinics, Zwolle, The Netherlands; 7HematoLogics, Inc., Seattle, WA, USA; 8Department of Hematology, Hospital Universitario de Guadalajara, Spain; 9HMDS, St. James’s University
    [Show full text]
  • Proposed Minimal Diagnostic Criteria for Myelodysplastic Syndromes (MDS) and Potential Pre-MDS Conditions
    www.impactjournals.com/oncotarget/ Oncotarget, 2017, Vol. 8, (No. 43), pp: 73483-73500 Priority Review Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions Peter Valent1,2, Attilio Orazi3, David P. Steensma4, Benjamin L. Ebert5, Detlef Haase6, Luca Malcovati7, Arjan A. van de Loosdrecht8, Torsten Haferlach9, Theresia M. Westers8, Denise A. Wells10, Aristoteles Giagounidis11, Michael Loken10, Alberto Orfao12, Michael Lübbert13, Arnold Ganser14, Wolf-Karsten Hofmann15, Kiyoyuki Ogata16, Julie Schanz6, Marie C. Béné17, Gregor Hoermann18, Wolfgang R. Sperr1,2, Karl Sotlar19, Peter Bettelheim20, Reinhard Stauder21, Michael Pfeilstöcker22, Hans- Peter Horny23, Ulrich Germing24, Peter Greenberg25 and John M. Bennett26 1 Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria 2 Ludwig Boltzmann Cluster Oncology, Medical University of Vienna, Vienna, Austria 3 Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, NY, USA 4 Division of Hematological Malignancies, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA 5 Division of Hematology, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA 6 Clinic of Hematology and Medical Oncology, Universitymedicine Göttingen, Göttingen, Germany 7 Department of Molecular Medicine, University of Pavia, Pavia, Italy 8 Department of Hematology Cancer Center Amsterdam,
    [Show full text]